Novel three-drug regimen used to manage life-threatening developments.
In April 2021, a 42-year-old man reached out to Brian Hill, MD, PhD, for a second opinion after being diagnosed with hairy cell leukemia following a bone marrow biopsy at a healthcare facility in northwest Ohio.
“At the time of diagnosis, he was getting easily fatigued and couldn’t exercise,” explains Dr. Hill, Director of the Lymphoid Malignancies Program at Cleveland Clinic’s Taussig Cancer Institute. “He was experiencing a slow-moving progression of symptoms.”
Standard front-line therapy for hairy cell lymphoma –an indolent B-cell lymphoproliferative disease – is the chemotherapy medication cladribine. Dr. Hill recommended the patient begin the drug, typically administered daily for five days or via a continuous pump for seven days, but the situation quickly pivoted.
“When I met the patient for a virtual second opinion, I recommended he get vaccinated against SARS-CoV-2 before beginning treatment,” says Dr. Hill. “Within two weeks, however, he was hospitalized with COVID-19 pneumonia.”
Severe COVID-19 sends patient to ICU
The patient was admitted to his local hospital with fever and shortness of breath. He tested positive for COVID-19, and within a few days, his breathing became more labored. He was transferred to Cleveland Clinic’s main campus.
“His critical illness was exacerbated by neutropenia from his leukemia,” says Dr. Hill. “Once he was admitted to our ICU, he rapidly deteriorated.” Within a few days, the patient was intubated and put on mechanical ventilation. His oxygenation levels were so poor that he was placed in the prone position and underwent pharmacologic paralysis.”
Unfortunately, the patient’s severe COVID had severely compromised his immune system. “The only way to improve his neutrophil and white blood cell counts was to get the cancer cells out of the bone marrow,” says Dr. Hill. However, the oncology team quickly realized that the standard chemotherapy approach for hairy cell leukemia could prove detrimental.
“He would unlikely survive short-term worsening of his neutropenia caused by the administration of traditional chemotherapy with cladribine,” explains Dr. Hill.
Second-line treatment given through NG tube
After discussions with other oncologists and the patient’s critical care team, including pulmonology specialists, Dr. Hill began to administer vemurafenib, an FDA-approved tablet medication for treating melanoma that targets mutations in the BRAF gene.
Approximately 90% of hairy cell leukemia cases also have this same BRAF mutation, says Dr. Hill. Although vemurafenib is not as effective as cladribine for hairy cell leukemia, the drug has been proven to be an effective second-line treatment.
Twice a day for more than two weeks, caregivers crushed a 960-mg tablet of vemurafenib and administered it to the patient through a nasogastric tube. He also was treated with remdesivir for COVID-19.
Gradually, the patient’s neutrophil count recovered, his breathing improved and his fever abated. He was weaned off high levels of oxygen.
“His COVID finally turned the corner,” says Dr. Hill. “I give most of the credit to our medical ICU nurses, pharmacists and physicians whose great work kept him going through all this.”
Complications, more treatment and remission
During his time in the hospital, the patient suffered numerous complications, including bacteremia, ventilator-associated pneumonia. He also lost some function in his left hand from neurologic compression of his brachial plexus.
After two months in the medical ICU, the patient was transferred to a medical-surgical unit in mid-June and was later discharged from the hospital July 1. His treatment journey for hairy cell leukemia continued throughout.
“While vemurafenib is a good drug, it wasn’t good enough in his case,” says Dr. Hill. “He stopped making progress while in the hospital, so we gave him a 70% dose of cladribine.” Once discharged, the patient received a standard dosage of the monoclonal antibody medication rituximab, which was necessary due to ongoing cytopenias.
“It was a balancing act to provide enough treatment against the hairy cell leukemia, but not so much to set him back in terms of infectious complications,” explains Dr. Hill.
A year after his hairy cell leukemia diagnosis, the patient is in remission. His only residual medical deficit is impaired inflection of his left wrist, for which he is undergoing physical therapy. The patient is back at home with his family, including his wife and three children. He hopes to return to work within the next few months.
“For patients like this one with rare diseases who have atypical treatment courses, it’s important to think outside the box to get the best outcomes. Cleveland Clinic excels at that,” says Dr. Hill. “In this case, we could not wait for the patient to get better from COVID to treat the cancer. We had to address both at once.”
News
Scientists Melt Cancer’s Hidden “Power Hubs” and Stop Tumor Growth
Researchers discovered that in a rare kidney cancer, RNA builds droplet-like hubs that act as growth control centers inside tumor cells. By engineering a molecular switch to dissolve these hubs, they were able to halt cancer [...]
Platelet-inspired nanoparticles could improve treatment of inflammatory diseases
Scientists have developed platelet-inspired nanoparticles that deliver anti-inflammatory drugs directly to brain-computer interface implants, doubling their effectiveness. Scientists have found a way to improve the performance of brain-computer interface (BCI) electrodes by delivering anti-inflammatory drugs directly [...]
After 150 years, a new chapter in cancer therapy is finally beginning
For decades, researchers have been looking for ways to destroy cancer cells in a targeted manner without further weakening the body. But for many patients whose immune system is severely impaired by chemotherapy or radiation, [...]
Older chemical libraries show promise for fighting resistant strains of COVID-19 virus
SARS‑CoV‑2, the virus that causes COVID-19, continues to mutate, with some newer strains becoming less responsive to current antiviral treatments like Paxlovid. Now, University of California San Diego scientists and an international team of [...]
Lower doses of immunotherapy for skin cancer give better results, study suggests
According to a new study, lower doses of approved immunotherapy for malignant melanoma can give better results against tumors, while reducing side effects. This is reported by researchers at Karolinska Institutet in the Journal of the National [...]
Researchers highlight five pathways through which microplastics can harm the brain
Microplastics could be fueling neurodegenerative diseases like Alzheimer's and Parkinson's, with a new study highlighting five ways microplastics can trigger inflammation and damage in the brain. More than 57 million people live with dementia, [...]
Tiny Metal Nanodots Obliterate Cancer Cells While Largely Sparing Healthy Tissue
Scientists have developed tiny metal-oxide particles that push cancer cells past their stress limits while sparing healthy tissue. An international team led by RMIT University has developed tiny particles called nanodots, crafted from a metallic compound, [...]
Gold Nanoclusters Could Supercharge Quantum Computers
Researchers found that gold “super atoms” can behave like the atoms in top-tier quantum systems—only far easier to scale. These tiny clusters can be customized at the molecular level, offering a powerful, tunable foundation [...]
A single shot of HPV vaccine may be enough to fight cervical cancer, study finds
WASHINGTON -- A single HPV vaccination appears just as effective as two doses at preventing the viral infection that causes cervical cancer, researchers reported Wednesday. HPV, or human papillomavirus, is very common and spread [...]
New technique overcomes technological barrier in 3D brain imaging
Scientists at the Swiss Light Source SLS have succeeded in mapping a piece of brain tissue in 3D at unprecedented resolution using X-rays, non-destructively. The breakthrough overcomes a long-standing technological barrier that had limited [...]
Scientists Uncover Hidden Blood Pattern in Long COVID
Researchers found persistent microclot and NET structures in Long COVID blood that may explain long-lasting symptoms. Researchers examining Long COVID have identified a structural connection between circulating microclots and neutrophil extracellular traps (NETs). The [...]
This Cellular Trick Helps Cancer Spread, but Could Also Stop It
Groups of normal cbiells can sense far into their surroundings, helping explain cancer cell migration. Understanding this ability could lead to new ways to limit tumor spread. The tale of the princess and the [...]
New mRNA therapy targets drug-resistant pneumonia
Bacteria that multiply on surfaces are a major headache in health care when they gain a foothold on, for example, implants or in catheters. Researchers at Chalmers University of Technology in Sweden have found [...]
Current Heart Health Guidelines Are Failing To Catch a Deadly Genetic Killer
New research reveals that standard screening misses most people with a common inherited cholesterol disorder. A Mayo Clinic study reports that current genetic screening guidelines overlook most people who have familial hypercholesterolemia, an inherited disorder that [...]
Scientists Identify the Evolutionary “Purpose” of Consciousness
Summary: Researchers at Ruhr University Bochum explore why consciousness evolved and why different species developed it in distinct ways. By comparing humans with birds, they show that complex awareness may arise through different neural architectures yet [...]
Novel mRNA therapy curbs antibiotic-resistant infections in preclinical lung models
Researchers at the Icahn School of Medicine at Mount Sinai and collaborators have reported early success with a novel mRNA-based therapy designed to combat antibiotic-resistant bacteria. The findings, published in Nature Biotechnology, show that in [...]
